[go: up one dir, main page]

WO2010048149A3 - Heterocyclic modulators of gpr119 for treatment of disease - Google Patents

Heterocyclic modulators of gpr119 for treatment of disease Download PDF

Info

Publication number
WO2010048149A3
WO2010048149A3 PCT/US2009/061281 US2009061281W WO2010048149A3 WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3 US 2009061281 W US2009061281 W US 2009061281W WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gpr119
disease
heterocyclic modulators
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/061281
Other languages
French (fr)
Other versions
WO2010048149A2 (en
Inventor
Nicholas D. Smith
Celine Bonnefous
Mehmet Kahraman
Stewart A. Noble
Joseph E. Payne
Steven P. Govek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of WO2010048149A2 publication Critical patent/WO2010048149A2/en
Publication of WO2010048149A3 publication Critical patent/WO2010048149A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed herein are compounds and methods which may be useful as inhibitors of GPR 119 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.
PCT/US2009/061281 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease Ceased WO2010048149A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10663808P 2008-10-20 2008-10-20
US61/106,638 2008-10-20
US14385409P 2009-01-12 2009-01-12
US61/143,854 2009-01-12
US15411509P 2009-02-20 2009-02-20
US61/154,115 2009-02-20

Publications (2)

Publication Number Publication Date
WO2010048149A2 WO2010048149A2 (en) 2010-04-29
WO2010048149A3 true WO2010048149A3 (en) 2010-09-02

Family

ID=42119931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061281 Ceased WO2010048149A2 (en) 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease

Country Status (1)

Country Link
WO (1) WO2010048149A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9758520B2 (en) 2014-04-04 2017-09-12 Sanofi Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US9896434B2 (en) 2014-04-04 2018-02-20 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US9908868B2 (en) 2014-04-04 2018-03-06 Sanofi Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US12054477B2 (en) 2021-09-15 2024-08-06 Hua Medicine (Shanghai) Ltd. Prodrug of pyrrolidone derivatives as glucokinase activator

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20110294836A1 (en) * 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CN102803214A (en) 2009-06-24 2012-11-28 贝林格尔.英格海姆国际有限公司 Novel compounds, pharmaceutical compositions and methods related thereto
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP5909185B2 (en) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド Substituted tetrazol-1-ylphenoxymethylthiazol-2-ylpiperidinylpyrimidine salt
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
MX2012004990A (en) 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS.
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013525371A (en) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド Method for producing cycloalkylcarboxamide-indole compound
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5847813B2 (en) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド Composition of 5-ethyl-2- {4- [4- (4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
WO2012006955A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
ES2551183T3 (en) 2010-10-08 2015-11-16 Cadila Healthcare Limited New GPR 119 agonists
SI2646444T1 (en) 2010-12-03 2016-09-30 Epizyme, Inc. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes
RU2013130253A (en) 2010-12-03 2015-01-10 Эпизайм, Инк. 7-DEAZAPURINE HISTONIC METHYL TRANSFERASES AND WAYS OF THEIR APPLICATION
US20120184572A1 (en) * 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
RU2608742C2 (en) 2011-03-28 2017-01-23 ЭмИАй ФАРМА, ИНК. (alpha-substituted aralkylamino- and heteroarylalkylamino)pyrimidinyl- and 1,3,5-triazinylbenzimidazoles, pharmaceutical compositions thereof and use thereof in treating proliferative diseases
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
HRP20190128T1 (en) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. NEW COMPOUNDS AS PROTEIN KINase MODULATORS
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
AR087701A1 (en) 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
CN106986863B (en) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 DNA-PK inhibitors
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR101535954B1 (en) 2012-06-12 2015-07-10 주식회사 종근당 Piperidine Derivatives for GPR119 agonist
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc DOT1L PROTEIN METHYLTRANSFERASE INHIBITORS AND METHODS OF USE
AU2013312319B2 (en) 2012-09-06 2018-04-19 Epizyme, Inc. Method of treating leukemia
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
AR092924A1 (en) 2012-10-09 2015-05-06 Sanofi Sa PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
HUE041544T2 (en) 2013-03-12 2019-05-28 Vertex Pharma Dna-pk inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
BR112015021985B1 (en) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS THEREOF, THEIR USES AND COMPOSITION
US9175032B2 (en) 2013-03-15 2015-11-03 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
MX2015014958A (en) * 2013-04-25 2016-03-07 Yuhan Corp Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same.
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
DK3013796T3 (en) * 2013-06-27 2020-03-16 Lg Chemical Ltd BIARLDER DERIVATIVES AS GPR120 AGONISTS
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
CA2920791C (en) 2013-10-14 2021-11-16 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
MA39034B1 (en) 2013-10-14 2018-09-28 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
WO2015058067A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
MX366297B (en) 2013-11-26 2019-07-04 Chong Kun Dang Pharmaceutical Corp Amide derivatives for gpr119 agonist.
HUE056297T2 (en) 2013-12-20 2022-02-28 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN111393431A (en) * 2014-01-06 2020-07-10 理森制药股份公司 glutaminase inhibitor
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (en) 2014-01-17 2019-02-08 Novartis Ag Derivatives of 1-pyridazin / triazin-3-yl-piper (-azine) / idine / pyrolidine and compositions thereof to inhibit the activity of SHP2
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
BR112016018555B1 (en) 2014-02-13 2024-01-23 Incyte Holdings Corporation CYCLOPROPYLAMINES AS LSD1 INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION COMPRISING THEM AND METHOD OF LSD1 INHIBITION
CN111454188A (en) 2014-02-13 2020-07-28 因赛特公司 Cyclopropylamines as L SD1inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ES2675858T3 (en) 2014-04-15 2018-07-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of diseases mediated by the cystic fibrosis transmembrane conductance regulator
NZ724878A (en) 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
ES2874561T3 (en) 2014-09-17 2021-11-05 Celgene Car Llc MK2 inhibitors and their uses
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
KR102659373B1 (en) 2015-04-03 2024-04-23 인사이트 홀딩스 코포레이션 Heterocyclic compounds as LSD1 inhibitors
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN107847765B (en) 2015-06-18 2021-05-04 89生物有限公司 1,4-Substituted piperidine derivatives
ES2741746T3 (en) 2015-06-19 2020-02-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN112625028B (en) 2015-06-19 2024-10-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
MX389824B (en) 2015-08-12 2025-03-20 Incyte Holdings Corp SALTS OF A LYSINE-SPECIFIC DIMETHYLASE 1 INHIBITOR (LSD1).
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
MY199968A (en) 2016-04-22 2023-11-30 Incyte Corp Formulations of an lsd1 inhibitor
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
PE20190971A1 (en) 2016-06-13 2019-07-09 Glaxosmithkline Ip Dev Ltd CHEMICAL COMPOUNDS
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN109715163B (en) 2016-09-19 2022-11-22 诺华股份有限公司 Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
JP2020514293A (en) 2017-01-06 2020-05-21 ユマニティ セラピューティクス，インコーポレーテッド How to treat neuropathy
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
EP3571193B1 (en) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Potassium channel modulators
EP3585775B1 (en) 2017-02-21 2022-04-06 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TWI798218B (en) 2017-05-02 2023-04-11 瑞士商諾華公司 Combination therapy
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. Combination therapy
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019036489A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
KR102717600B1 (en) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. Inhibition of ubiquitin-specific peptidase 30
JP7517992B2 (en) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． Compounds and their uses
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
TWI707683B (en) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Glp-1 receptor agonists and uses thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CR20210175A (en) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
SMT202300164T1 (en) 2018-10-05 2023-07-20 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
MA53978A (en) 2018-10-22 2021-09-01 Cadent Therapeutics Inc CRYSTALLINE FORMS OF POTASSIUM CHANNEL MODULATORS
CN113272280B (en) 2018-11-06 2026-01-09 艾知怀斯治疗学公司 Pyridazinone compounds and their uses
CN113272014B (en) 2018-11-06 2026-01-27 艾知怀斯治疗学公司 Pyridazinone compounds and uses thereof
HRP20231389T1 (en) 2018-11-06 2024-03-01 Edgewise Therapeutics, Inc. PYRIDAZINONE COMPOUNDS AND THEIR USES
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
JP2022518016A (en) 2019-01-18 2022-03-11 アストラゼネカ・アクチエボラーグ PCSK9 inhibitor and its usage
CN113906019A (en) 2019-01-24 2022-01-07 优曼尼蒂治疗公司 Compound and use thereof
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
CN114072408B (en) * 2019-07-08 2023-05-12 南京明德新药研发有限公司 Compounds as inhibitors of porcupine and uses thereof
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
CR20220316A (en) 2019-12-06 2022-10-07 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
BR112022017039A2 (en) 2020-02-28 2022-11-16 Kallyope Inc GPR40 AGONISTS
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
JP2023531726A (en) 2020-06-26 2023-07-25 キャリーオペ，インク． AMPK Activator
WO2022147246A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
MX2023009685A (en) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof.
BR112023016614A2 (en) 2021-02-19 2023-11-07 Sudo Biosciences Ltd TYK2 INHIBITORS AND USES THEREOF
HRP20251504T1 (en) 2021-06-04 2026-01-02 Vertex Pharmaceuticals Incorporated N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS
CN117813098A (en) * 2021-08-13 2024-04-02 苏州亚盛药业有限公司 A method of treating a disease or condition
CN113480522A (en) * 2021-08-19 2021-10-08 守恒(厦门)医疗科技有限公司 Novel phenylpyrazole derivative and application thereof in hypoglycemic drugs
WO2023166346A1 (en) 2022-03-02 2023-09-07 Horizon Therapeutics Ireland Dac Process of making a crystalline edg-2 receptor antagonist
AU2023256603A1 (en) 2022-04-22 2024-11-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9758520B2 (en) 2014-04-04 2017-09-12 Sanofi Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US9896434B2 (en) 2014-04-04 2018-02-20 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US9908868B2 (en) 2014-04-04 2018-03-06 Sanofi Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US12054477B2 (en) 2021-09-15 2024-08-06 Hua Medicine (Shanghai) Ltd. Prodrug of pyrrolidone derivatives as glucokinase activator

Also Published As

Publication number Publication date
WO2010048149A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2010062863A3 (en) Compositions containing satiogens and methods of use
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
PL2118074T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
PL2234621T3 (en) Compositions and methods for treating diseases of the nail
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2006084015A3 (en) Raf inhibitor compounds and methods
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
PL2288364T3 (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
PL3216457T3 (en) Compounds and methods for the prevention or treatment of restenosis
WO2010014739A3 (en) Heterocyclic modulators of tgr5
SI2234631T1 (en) Compounds and methods for the treatment of vascular disease
PT1828151E (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer`s disease
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
WO2010011684A3 (en) Prodrug and fluoregenic compositions and methods for using the same
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2007115287A3 (en) Combination of organic compounds
WO2009158387A3 (en) Compositions, formulations, and methods for preventing and/or treating physical effects of alcohol consumption

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2